1stOncology™: Cancer Intelligence Service – Page 14293 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Myovant Sciences to Present at Upcoming Investor Conferences

On March 6, 2018 Myovant Sciences (NYSE: MYOV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women’s health and endocrine diseases, reported that Lynn Seely, M.D., President and Chief Executive Officer of Myovant Sciences, will present at the following investor conferences (Press release, Myovant Sciences, MAR 6, 2018, http://investors.myovant.com/news-releases/2018/03-06-2018-220102504 [SID1234524457]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Cowen 38th Annual Healthcare Conference on Monday March 12, 2018 at 2:50 p.m. ET
Barclays Global Healthcare Conference on Tuesday March 13, 2018 at 10:15 a.m. ET

The events will be webcast live and may be accessed via the Events page under the Investors and Media section of Myovant’s website at www.myovant.com. Please connect to the company’s website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast. A replay will also be available at the same location for 30 days following the conference.

Moleculin to Present at the 30th Annual ROTH Conference Tuesday, March 13, 2018

On March 6, 2018 Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center ("MD Anderson"), reported that Walter Klemp, chief executive officer and Jon Foster, chief financial officer, will present at the 30th Annual ROTH Conference on Tuesday, March 13, 2018 at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time) in Yellow – Salon 6 (Press release, Moleculin, MAR 6, 2018, View Source [SID1234524456]). The conference is being held at the Ritz-Carlton Hotel in Dana Point, California from March 11-14, 2018.

A webcast of the presentation will be available at the Investor Relations page of the Company’s website at www.moleculin.com. The webcast and presentation will be archived on the Company’s website for 90 days following the event.

The Company will also host investor meetings throughout the day on Tuesday, March 13, 2018. Attendance at the conference is by invitation only for clients of ROTH Capital Markets. Interested investors should contact your ROTH Capital Markets sales representative or Lytham Partners at (602) 889-9700 or mbrx@lythampartners.com to secure a meeting time.

MOLECULAR PARTNERS TO PRESENT AT THE COWEN AND COMPANY 38th ANNUAL HEALTHCARE CONFERENCE

On March 6, 2018 Molecular Partners AG (ticker: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin therapies*, reported that it will present at the Cowen and Company 38th Annual Healthcare Conference on Tuesday, March 13, 2018 at 8:00 ET (2:00 PM CET) (Press release, Molecular Partners, MAR 6, 2018, View Source [SID1234524455]).

The presentation, followed by a breakout session, will be hosted by Dr. Patrick Amstutz, CEO of Molecular Partners and Dr. Michael Stumpp, CSO of the company.

The presentation will be webcast live and can be accessed on the day via this link. A copy of the presentation handout as well as a replay of the webcast will be made available on the company’s website www.molecularpartners.com under the Investors section. The replay will be available for 90 days following the presentation.

Loxo Oncology to Present at the Cowen and Company 38th Annual Health Care Conference

on March 6, 2018 Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, reported that Joshua H. Bilenker, M.D., chief executive officer, will present a corporate overview at the Cowen and Company 38th Annual Health Care Conference in Boston on Tuesday, March 13, 2018 at 10:00 a.m. ET (Press release, Loxo Oncology, MAR 6, 2018, View Source [SID1234524454]).

A live broadcast of the presentation will be available at View Source An archived replay of the presentation will be available on the company’s website for 30 days following the presentation.

Kura Oncology to Present at Cowen and Company 38th Annual Health Care Conference

On March 6, 2018 Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, reported its participation in the Cowen and Company 38th Annual Health Care Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to present an overview of the company on Tuesday, March 13, 2018 at 8:40 a.m. ET / 5:40 a.m. PT (Press release, Kura Oncology, MAR 6, 2018, http://ir.kuraoncology.com/news-releases/news-release-details/kura-oncology-present-cowen-and-company-38th-annual-health-care [SID1234524453]). The conference will be held from March 12-14, 2018 in Boston.

A live audio webcast of the presentation will be available in the Investors section of Kura Oncology’s website at www.kuraoncology.com, with an archived replay available for 30 days following the event.